Article
Hematology
Sophia Ahmed, Paul Glover, Jan Taylor, Chulin Sha, Matthew A. Care, Reuben Tooze, Andrew Davies, David R. Westhead, Peter W. M. Johnson, Catherine Burton, Sharon L. Barrans
Summary: Subclassification of diffuse large B cell lymphoma into cell-of-origin categories using gene expression profiling shows high level of concordance across different platforms, with confidence value being crucial in clinical applications.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Ye Shen, Lihong Wang, Jinping Ou, Bingjie Wang, Xinan Cen
Summary: This study investigated the expression and prognostic value of 5-hydroxymethylcytosine (5-hmC) in primary testicular diffuse large B-cell lymphoma (PT-DLBCL). The results showed that relatively low 5-hmC expression can serve as a poor prognostic predictor for PT-DLBCL, indicating the need for further research on the underlying mechanism of this epigenetic marker to provide new targets for cancer therapy.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2022)
Article
Health Care Sciences & Services
Yu-Fen Tsai, Yi-Chang Liu, Ching- Yang, Tzer-Ming Chuang, Ya-Lun Ke, Tsung-Jang Yeh, Yuh-Ching Gau, Jeng-Shiun Du, Hui-Ching Wang, Shih-Feng Cho, Chin-Mu Hsu, Pey-Fang Wu, Ching- Huang, Chung-Feng Huang, Ming-Lung Yu, Chia-Yen Dai, Hui-Hua Hsiao
Summary: HCV-positive DLBCL patients show poorer performance status, higher complication rates, and intolerance to treatment, leading to fewer treatment cycles and inferior survival outcomes.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Husain Yar Khan, Md. Hafiz Uddin, Suresh Kumar Balasubramanian, Noor Sulaiman, Marium Iqbal, Mahmoud Chaker, Amro Aboukameel, Yiwei Li, William Senapedis, Erkan Baloglu, Ramzi M. Mohammad, Jeffrey Zonder, Asfar S. Azmi
Summary: Targeting PAK4 and NAMPT using the small molecule inhibitor KPT-9274 can inhibit cell proliferation, deplete energy, and induce apoptosis in various NHL subtypes. KPT-9274 treatment shows potent anti-tumor effects in experimental models, suggesting its potential as a novel therapy for NHL.
Article
Hematology
Haiyan Yang, Bing Xiang, Yuqin Song, Huilai Zhang, Weili Zhao, Dehui Zou, Fangfang Lv, Wei Guo, Aichun Liu, Caixia Li, Ziwen Tan, Yang Liu, Lina Fu, Haiyi Guo, William Novotny, Jane Huang, Yufu Li
Summary: BTK inhibitors, such as zanubrutinib, have shown modest antitumor activity in non-GCB DLBCL, with potential efficacy in patients with CD79B and MYD88 mutations.
Article
Biophysics
Taha Al-Juhaishi, Yingjun Wang, Denai R. Milton, Zijun Y. Xu-Monette, Elias Jabbour, May Daher, Jin S. Im, Qaiser Bashir, Swaminathan P. Iyer, David Marin, Amanda L. Olson, Uday Popat, Muzaffar Qazilbash, Gabriela Rondon, Alison M. Gulbis, Richard E. Champlin, Ken H. Young, Issa F. Khouri
Summary: Dual expression of MYC and BCL2 proteins (DEL) and cell of origin (COO) are important prognostic factors in DLBCL patients after chemotherapy. The study found that DEL/DHL had worse overall survival compared to DEL/non-DHL, and DEL/DHL, age >60 years, and >2 prior therapies were important prognostic factors for overall survival on multivariable analysis. The impact of COO on prognosis was not significant.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Dario Marino, Marco Pizzi, Iuliia Kotova, Ronny Schmidt, Christoph Schroeder, Vincenza Guzzardo, Ilaria Talli, Edoardo Peroni, Silvia Finotto, Greta Scapinello, Angelo Paolo Dei Tos, Francesco Piazza, Livio Trentin, Vittorina Zagonel, Erich Piovan
Summary: This study identifies two proteins that are important for predicting the survival of patients with diffuse large B-cell lymphoma (DLBCL). Additionally, the expression levels of one of these proteins can predict sensitivity to a specific death-inducing drug, suggesting personalized treatment options. The oncogenic function of ETV6 in DLBCL is also highlighted.
Article
Cell Biology
Baoping Cao, Xiaochuan Guo, Lefu Huang, Bin Wang, Weixia Wang, Dong Han, Weijing Zhang, Kaili Zhong
Summary: The study demonstrated that in patients with diffuse large B-cell lymphoma, reduced expression of CDH23 due to DNA methylation was associated with poor prognosis. Functional enrichment analysis showed that CDH23 plays important roles in cancer cell growth, cell metastasis, and immunity.
Article
Oncology
Dan Guo, Yuming Wang, Xunyao Wu, Yike Gao, Anqi Wang, Zixin Zhang, Kun Zhao, Xiaoxi Wang, Meiyu Liu, Yaran Zhang, Mei Li, Rui Chen, Jian Sun, Yan Zhang
Summary: Metabolites of tryptophan (Trp) metabolism in the tumor microenvironment play crucial immunosuppressive roles in diffuse large B-cell lymphoma (DLBCL) and natural killer/T-cell lymphoma (NK/TCL). The potential role of Trp metabolism was investigated in DLBCL and NK/TCL patients, and the expression of IDO1, IDO2, TDO2, and IL4I1 was analyzed. However, there was no significant difference in the positivity of these enzymes between PD-L1+ and PD-L1- tissue samples in NK/TCL patients.
Article
Biochemistry & Molecular Biology
Ying Fang, Mu-Chen Zhang, Yang He, Chen Li, Hai Fang, Peng-Peng Xu, Shu Cheng, Yan Zhao, Yan Feng, Qian Liu, Li Wang, Wei-Li Zhao
Summary: This study assessed the impact of TP53 mutation on diffuse large B-cell lymphoma (DLBCL) and its role in DLBCL treatment. The results showed that TP53 mutation is associated with poor prognosis in DLBCL patients treated with R-CHOP, but this effect can be mitigated by DR-CHOP treatment. TP53 mutation also leads to immune modulation repression and increased expression of SUV39H1 and H3K9 trimethylation, resulting in the inhibition of endogenous retroviruses (ERVs) and the formation of an immunosuppressive tumor microenvironment.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Qianhui Gu, Jing Li, Zhuolin Chen, Jie Zhang, Hui Shen, Xiaobing Miao, Ying Zhou, Xiaohong Xu, Song He
Summary: Recent studies have shown that PD-L2 expression is associated with clinicopathological features in DLBCL patients. Higher expression of PD-L2 is correlated with better prognosis and survival outcomes, indicating its potential as a therapeutic target in DLBCL.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Zhengzi Qian, Leiyuan Chen, Xinyuan Wang, Yutian Kan, Yafei Wang, Yong Yu, Xiaofang Wang, Zhigang Zhao, Hongliang Yang, Peng Ge, Tingting Ding, Qiongli Zhai, Haifeng Zhao
Summary: The study showed that upregulation of MALAT1 is associated with poor overall survival and progression-free survival in patients with PGI-DLBCL, suggesting its potential as a prognostic biomarker and therapeutic target.
CLINICAL AND EXPERIMENTAL MEDICINE
(2022)
Article
Pathology
Jin Roh, Hyungwoo Cho, Hyo-Kyung Pak, Yoon Sei Lee, Sang-wook Lee, Jin-Sook Ryu, Eun Jin Chae, Kyung Won Kim, Jooryung Huh, Yoon Seok Choi, Seong Hyun Jeong, Cheolwon Suh, Dok Hyun Yoon, Chan-Sik Park
Summary: The study evaluated the prognostic value of BCL2 expression in DLBCL patients and found that BCL2 super-expressors had worse survival outcomes. The study suggests that BCL2 super-expression characterizes a distinct subset of DLBCL with poor prognosis and may be a potential target population for BCL-2 inhibitors.
Article
Oncology
Elizabeth Punnoose, Franklin Peale, Edith Szafer-Glusman, Guiyuan Lei, Richard Bourgon, An D. Do, Eugene Kim, Liping Zhang, Pedro Farinha, Randy D. Gascoyne, F. Javier Munoz, Maurizio Martelli, Anja Mottok, Gilles A. Salles, Laurie H. Sehn, John F. Seymour, Marek Trneny, Mikkel Z. Oestergaard, Kirsten E. Mundt, Umberto Vitolo
Summary: The expression of BCL2 in patients with DLBCL is associated with a poorer progression-free survival. The study supports the use of an IHC scoring system to select BCL2-positive patients for future research.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Review
Immunology
Ana Carolina Caballero, Laura Escriba-Garcia, Carmen Alvarez-Fernandez, Javier Briones
Summary: Immunotherapy using genetically modified T cells has shown significant efficacy in patients with relapsed/refractory B-cell lymphoma. However, more than 50% of patients do not benefit from this therapy. Understanding the clinical and biological features that predict response to this therapy is crucial for selecting patients with higher chances of response. Recent advances have been made in the treatment of diffuse large B-cell lymphoma with CAR-T cells, and the impact of biological features of the CAR-T product on clinical response is also discussed.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
Eduardo Dutra, Tiago Maia, Jose Cabecadas
Summary: We report a case of primary cutaneous anaplastic large cell lymphoma with a 6p25.3 rearrangement. Despite multiple relapses, the disease progressed to a distant lymph node indolently.
AMERICAN JOURNAL OF DERMATOPATHOLOGY
(2022)
Article
Hematology
Livio Pagano, Jon Salmanton-Garc, Francesco Marchesi, Alberto Lopez-Garcia, Sylvain Lamure, Federico Itri, Maria Gomes-Silva, Giulia Dragonetti, Iker Falces-Romero, Jaap van Doesum, Uluhan Sili, Jorge Labrador, Maria Calbacho, Yavuz M. Bilgin, Barbora Weinbergerova, Laura Serrano, Jose-Maria Ribera-Santa Susana, Sandra Malak, Jose Loureiro-Amigo, Andreas Glenthoj, Raul Cordoba-Mascunano, Raquel Nunes-Rodrigues, Tomas-Jose Gonzalez-Lopez, Linda Katharina Karlsson, Maria-Josefa Jimenez-Lorenzo, Jose-Angel Hernandez-Rivas, Ozren Jaksic, Zdenek Racil, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolai Klimko, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, Oliver A. Cornely
Article
Hematology
Ana Carolina Freitas, Ines Patrocinio Carvalho, Susana Esteves, Lucilia Salgado, Maria Gomes da Silva
Summary: This study highlights the importance of using EOT FDG-PET for treatment decisions in primary mediastinal B-cell lymphoma, showing a high negative predictive value. The results demonstrate that patients with negative EOT FDG-PET have better progression-free survival and overall survival rates.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Herve Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N. Libby, Rene-Olivier Casasnovas, Ian W. Flinn, Corinne Haioun, Herve Maisonneuve, Loic Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas Daguindau, Stephanie Guidez, Gian Matteo Pica, Alejandro Martin Garcia-Sancho, Armondo Lopez-Guillermo, Jean-Francois Larouche, Kiyoshi Ando, Maria Gomes da Silva, Marc Andre, Wu Kalung, Laurie H. Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan H. Fowler, Gilles Salles
Summary: The second interim analysis of the RELEVANCE trial after 6 years of follow-up showed that lenalidomide plus rituximab provided similar efficacy to rituximab plus chemotherapy in patients with advanced-stage follicular lymphoma. It demonstrated comparable, durable efficacy and safety, offering a chemo-free alternative for previously untreated patients with FL.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Sonia Matos, Paulo Bernardo, Susana Esteves, Aida Botelho de Sousa, Marcos Lemos, Patricia Ribeiro, Madalena Silva, Albertina Nunes, Joana Lobato, Maria de Jesus Frade, Maria Gomes da Silva, Sergio Chacim, Jose Mariz, Graca Esteves, Joao Raposo, Ana Espadana, Jose Carda, Pedro Barbosa, Vania Martins, Maria Carmo-Fonseca, Joana Desterro
Summary: This study aimed to evaluate the clinical value of screening a targeted gene panel by next-generation sequencing (NGS) in acute myeloid leukemia (AML) patients. The researchers prospectively analyzed 268 newly diagnosed AML patients and found that access to NGS data improved risk assessment for approximately 23% of the patients, leading to unexpected results associated with mutations in the FLT3 gene. The study demonstrates the prognostic utility of screening AML patients for multiple gene mutations by NGS and emphasizes the need for further studies to refine the current risk classification criteria.
Article
Hematology
Livio Pagano, Jon Salmanton-Garcia, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthoj, Jaap van Doesum, Yavuz M. Bilgin, Alberto Lopez-Garcia, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerova, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens van Praet, Ozren Jaksic, Toni Valkovic, Iker Falces-Romero, Sonia Martin-Perez, Moraima Jimenez, Julio Davila-Valls, Martin Schonlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, Laszlo Imre Pinczes, Caterina Buquicchio, Klara Piukovics, Irati Ormazabal-Velez, Nicola Fracchiolla, Michail Samarkos, Gustavo-Adolfo Mendez, Jose-Angel Hernandez-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta di Blasi, Joyce Marques de Almedia, Michelina Dargenio, Monika M. Biernat, Mariarita Sciume, Cristina de Ramon, Nick de Jonge, Josip Batinic, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemi Fernandez, Giovanni Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirkan, Lucia Prezioso, Zdenek Racil, Marcio Nucci, Milos Mladenovic, Raphael Lievin, Michaela Hanakova, Stefanie Grafe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adzic-Vukicevic, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A. Cornely
Summary: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-SARS-CoV-2 vaccination. This study found a relatively low mortality rate among patients with breakthrough COVID-19, with the Omicron variant being the predominant strain. Patients receiving monoclonal antibody treatment had a lower mortality rate.
Article
Biochemistry & Molecular Biology
Rune Matthiesen, Paula Gameiro, Andreia Henriques, Cristian Bodo, Maria Carolina Strano Moraes, Bruno Costa-Silva, Jose Cabecadas, Maria Gomes da Silva, Hans Christian Beck, Ana Sofia Carvalho
Summary: This study characterized and evaluated the proteome of plasma extracellular vesicles in DLBCL patients, and found that these proteins are closely associated with the status of DLBCL and may serve as prognostic markers for patient survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Hematology
Catherine Thieblemont, Loic Chartier, Ulrich Duhrsen, Umberto Vitolo, Sally F. Barrington, Jan M. Zaucha, Laetitia Vercellino, Maria Gomes Silva, Ines Patrocinio-Carvalho, Pierre Decazes, Pierre-Julien Viailly, Herve Tilly, Alina Berriolo-Riedinger, Oliver Casasnovas, Andreas Huttmann, Hajira Ilyas, N. George Mikhaeel, Joel Dunn, Anne-Segolene Cottereau, Christine Schmitz, Lale Kostakoglu, Joseph N. Paulson, Tina Nielsen, Michael Meignan
Summary: This study validated a combination model using total metabolic tumor volume and performance status to accurately identify risk categories of patients with aggressive large B-cell lymphoma. The combination model can better predict patients' prognosis before treatment and help determine who will benefit the most from therapy.
Article
Oncology
Chiara Cattaneo, Jon Salmanton-Garcia, Francesco Marchesi, Shaimaa El-Ashwah, Federico Itri, Barbora Weinbergerova, Maria Gomes Da Silva, Michelina Dargenio, Julio Davila-Valls, Sonia Martin-Perez, Francesca Farina, Jaap Van Doesum, Toni Valkovic, Caroline Besson, Christian Bjorn Poulsen, Alberto Lopez-Garcia, Pavel Zak, Martin Schonlein, Klara Piukovics, Ozren Jaksic, Alba Cabirta, Natasha Ali, Uluhan Sili, Nicola Fracchiolla, Giulia Dragonetti, Tatjana Adzic-Vukicevic, Monia Marchetti, Marina Machado, Andreas Glenthoj, Olimpia Finizio, Fatih Demirkan, Ola Blennow, Maria Chiara Tisi, Ali S. Omrani, Milan Navratil, Zdenek Racil, Jan Novak, Gabriele Magliano, Moraima Jimenez, Carolina Garcia-Vidal, Nurettin Erben, Maria Ilaria Del Principe, Caterina Buquicchio, Rui Bergantim, Josip Batinic, Murtadha Al-Khabori, Luisa Verga, Tomas Szotkowski, Michail Samarkos, Irati Ormazabal-Velez, Stef Meers, Johan Maertens, Laszlo Imre Pinczes, Martin Hoenigl, L'ubos Drgona, Annarosa Cuccaro, Yavuz M. Bilgin, Avinash Aujayeb, Laman Rahimli, Stefanie Grafe, Mariarita Sciume, Milos Mladenovic, Gokce Melis Colak, Maria Vittoria Sacchi, Anna Nordlander, Caroline Berg Venemyr, Michaela Hanakova, Nicole Garcia-Pouton, Ziad Emarah, Giovanni Paolo Maria Zambrotta, Raquel Nunes Rodrigues, Raul Cordoba, Gustavo-Adolfo Mendez, Monika M. Biernat, Oliver A. Cornely, Livio Pagano
Summary: Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 pose a greater challenge for hematologists. It was found that patients not receiving HM treatment had a higher mortality rate, and age, severe/critical COVID-19, >= 2 comorbidities, and lack of HM treatment were identified as independent risk factors for mortality. These observations highlight the importance of HM treatment in these patients.
Review
Cell Biology
Mostafa Ejtehadifar, Sara Zahedi, Paula Gameiro, Jose Cabecadas, Maria Gomes da Silva, Hans C. Beck, Ana Sofia Carvalho, Rune Matthiesen
Summary: Mass spectrometry-based proteomics has identified proteins as diagnostic, prognostic, and druggable targets in diffuse large B cell lymphoma. We reviewed these studies and extracted the most consistently significantly regulated proteins, including interferon regulatory factor4, annexinA5, and nucleobindin1.
Article
Hematology
Ana Carolina Freitas, Tiago Maia, Joana Desterro, Francesca Pierdomenico, Albertina Nunes, Isabelina Ferreira, Jose Cabecadas, Maria Gomes da Silva
Summary: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are a diverse group of diseases that are increasingly classified based on recurrent genetic abnormalities. Chromosomal translocations involving meningioma 1 (MN1) and ETS variant 6 (ETV6) genes are rare but common in myeloid neoplasms. We present a case of MDS/MPN with neutrophilia that developed an extramedullary T-lymphoblastic crisis with the t(12;22)(p13;q12) translocation as the only cytogenetic abnormality. This case shares characteristics with myeloid/lymphoid neoplasms with eosinophilia and highlights the importance of molecular characterization in classification and prognostic stratification.
HEMATOLOGY REPORTS
(2023)
Article
Health Care Sciences & Services
Denis Horgan, Jan Walewski, Igor Aurer, Carlo Visco, Eva Gine, Bogdan Fetica, Mats Jerkeman, Marta Kozaric, Maria Gomes da Silva, Martin Dreyling
Summary: An expert panel convened by EAPM discussed the achievements and challenges in mantle cell lymphoma in Europe, pointing out barriers to better care and proposing solutions through closer coordination and policy changes at national and EU levels.